In8bio Inc

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for cancer and autoimmune diseases. Its lead candidates include INB-400 in Phase 2 for newly diagnosed glioblastoma (GBM), INB-200 in Phase 1 for GBM, and INB-100 in Phase 1 for hematologic malignancies in patients undergoing hematopoietic stem cell transplantation. The company also develops INB-619, INB-300, INB-500, and INB-600. Formerly Incysus Therapeutics, Inc., it changed its name to IN8bio, Inc. in August 2020, was incorporated in 2016, and is headquartered in New York, New York.